Skip to main content

ScholarsBetaWeill Cornell Medicine

Browse About Sign in

Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research8

FiltersClear all

Status

Recruiting3
Active, not recruiting2
Completed1
Terminated2

Study type

Interventional8

Phase

Phase 18
Phase 1/26
Phase 25
Phase 32
Not applicable2
Not reported2

Investigator

Pinkal Desai2
Ellen K. Ritchie2
Caitlin K Gribbin1
Erin Mulvey1
Gail J Roboz1

Show all 6Show fewer

Department

Medicine8

Condition

Recurrence8
Leukemia, Myeloid, Acute22
Lymphoma, Non-Hodgkin10
Multiple Myeloma10
Myelodysplastic Syndromes10

Intervention type

Drug7
Biological1

Sponsor type

Industry7
Other academic1

Start date

to

Has results posted1

Phase 1×Recurrence×Clear all

Showing 1–8 of 8 studiesSort:

RecruitingInterventional · Phase 1NCT02074839 ↗
A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Phase 2/3

1

Sebastian A. Mayer1

Show all 50

Show fewer

Intervention: Drug: AG-120
Dates: Mar 2014 – Dec 2026 (est.)
Sponsor: Agios Pharmaceuticals, Inc.

Relapsed or Refractory Acute Myeloid Leukemia (AML)Untreated AMLOther IDH1-mutated Positive Hematologic Malignancies+1 more

Active, not recruitingInterventional · Phase 1NCT04279847 ↗

A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Ellen K. RitchiePI

Intervention: Drug: INCB057643 · Drug: Ruxolitinib
Dates: Feb 2021 – Apr 2027 (est.)
Sponsor: Incyte Corporation

MyelofibrosisMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome+4 more

Active, not recruitingInterventional · Phase 1NCT04420754 ↗

A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid Cancer

Sebastian A. MayerPI

Intervention: Biological: AIC100 CAR T Cells
Dates: Sep 2020 – Aug 2026 (est.)
Sponsor: AffyImmune Therapeutics Inc.

Anaplastic Thyroid CancerRelapsed/Refractory Poorly Differentiated Thyroid Cancer

RecruitingInterventional · Phase 1NCT05798897 ↗

A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)

Caitlin K GribbinPI

Intervention: Drug: MT-601
Dates: Jan 2023 – Feb 2028 (est.)
Sponsor: Marker Therapeutics, Inc.

Non-Hodgkin Lymphoma, AdultNon-Hodgkin Lymphoma, RefractoryNon-Hodgkin Lymphoma, Relapsed+4 more

RecruitingInterventional · Phase 1NCT07082803 ↗

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas

Intervention: Drug: TLN-121 · Drug: zeprumetostat (TLN-254)
Dates: Jun 2025 – Sep 2030 (est.)
Sponsor: Treeline Biosciences INC

LymphomaLymphoma, Non Hodgkin

TerminatedInterventional · Phase 1NCT03218683 ↗

A Phase 1/1b/2a, 3-Part, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 Monotherapy and in Combination With Venetoclax in Subjects With Relapsed or Refractory Haematologic Malignancies

Intervention: Drug: AZD5991 · Drug: AZD5991 + Venetoclax
Dates: Aug 2017 – Oct 2021
Sponsor: AstraZeneca Pharmaceuticals LP

Relapsed or Refractory Acute Myeloid Leukemia (AML)

CompletedInterventional · Phase 1NCT03625505 ↗

A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Ellen K. RitchiePI

Intervention: Drug: Venetoclax · Drug: Gilteritinib
Dates: Oct 2018 – Aug 2021
Sponsor: AbbVie Inc.

Acute Myeloid Leukemia (AML)

TerminatedInterventional · Phase 1NCT05787496 ↗

A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms

Intervention: Drug: NC525
Dates: Feb 2023 – Jan 2025· Results posted
Sponsor: NextCure, Inc.

Relapsed or Refractory Acute Myeloid LeukemiaRelapsed or Refractory Chronic Myelomonocytic LeukemiaRelapsed or Refractory Myelodysplastic Syndrome